Key points are not available for this paper at this time.
Over 2 decades ago, the idea for a polypill emerged as a plausible solution to reduce the global burden of cardiovascular disease (CVD) in low- and middle-income countries.1 Although with imperfect implementation and real-world challenges, a polypill is available outside the US.
Yancy et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: